AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 23- Open
- $267.83
- 52-wk high
- $276.47
- High
- $272.66
- 52-wk low
- $170.33
- Low
- $267.00
- Prev close
- $267.37
Smart money
Earnings
Earnings came in 2.1% above what analysts expected.
Financials
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $23.99B | $24.56B | $24.06B | $25.31B |
| Cost of what it sold | $7.30B | $7.97B | $6.86B | $6.81B |
| Gross profit | $16.69B | $16.60B | $17.20B | $18.50B |
| What it spent | ||||
| Research and development | $3.67B | $4.25B | $3.53B | $3.65B |
| Sales and admin | $5.92B | $6.95B | $6.03B | $6.43B |
| Other operating costs | — | -$200.0M | $1.25B | $1.25B |
| Total operating expenses | $9.59B | $11.01B | $10.81B | $11.33B |
| What was left | ||||
| Operating profit | $7.10B | $5.59B | $6.39B | $7.17B |
| Interest on debt | $245.0M | $214.0M | $272.0M | $281.0M |
| Profit before tax | $7.49B | $4.97B | $5.99B | $6.75B |
| Tax | $2.34B | -$150.0M | $755.0M | $1.21B |
| Net profit | $5.15B | $5.12B | $5.24B | $5.53B |
| EBITDA | $9.29B | $7.19B | $8.27B | $8.99B |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
72overbought
20D volatility
22%annualized
52-week range
$170.33$276.47
20D support
News
What the news says
50 articles · 7 days
Coverage is bullish
Tone of tracked coverage
Is The Depo-Provera Meningioma Settlement Reshaping Legal Risk In Pfizer’s Investment Case (PFE)?
NeutralAug 22Great Lakes Advisors LLC Makes New Investment in Kenvue Inc. $KVUE
NeutralAug 22Summit Therapeutics (NASDAQ:SMMT) Clinical Pathway Gains Fresh Attention
Leans bullishAug 22
